[{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Parkinson\u2019s Foundation","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Parkinson\u2019s Foundation"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AFM24","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NKGen Biotech \/ Affimed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Affimed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"HekaBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ HekaBio","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ HekaBio"}]
Find Clinical Drug Pipeline Developments & Deals by NKGen Biotech
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
